20
Mylan Laboratories Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is SUGAMMADEX SODIUM, with a corresponding US DMF Number 32311.
Remarkably, this DMF maintains an Active status since its submission on January 07, 2018, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of October 31, 2018, and payment made on September 14, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II